|
| | Overall survival rate at 1 year after transplant (%) | Overall survival rate at 2 years after transplant (%) | Overall survival rate at 3 years after transplant (%) | Overall survival rate at 4 years after transplant (%) | Overall survival rate at 5 years after transplant (%) | Mortality risk ratio (SRL : CNI) |
|
| Maintenance dosing |
| Toso et al. Hepatology. 2010; 51: 1237–43 [65] | | | 85.6 versus 79.2 (SRL versus SRL-free) | | 83.1 versus 68.7 (SRL versus SRL-free, ) | |
| Kneteman et al. Liver Transpl. 2004; 10: 1301–11 [63] | 94.1 (Milan criteria) 90.5 (extended criteria) | | | 81.1 (Milan criteria), 76.8 (extended criteria) | | |
|
| De novo dosing |
| Chinnakotla et al. Liver Transpl. 2009; 15: 1834–42 [55] | 94 versus 79 (SRL versus TAC) | | 85 versus 66 (SRL versus TAC) | | 80 versus 59 (SRL versus TAC, ) | |
| Zhou et al. Transplant Proc. 2008; 40: 3548–53 [59] | 90.67 versus 61.60 (SRL versus TAC, ) | 80.59 versus 53.90 (SRL versus TAC, ) | | | | |
| Zimmerman et al. Liver Transpl. 2008; 14: 633–8 [15] | 95.5 versus 83 (SRL versus CNI) | | | | 78.8 versus 62 (SRL versus CNI) | 0.672 |
|
| Late conversion (>3 months after transplantation) |
| Vivarelli et al. Transplant Proc. 2010; 42: 2579–84 [80] | | | 84 | | | |
|
